Although senior leadership has been re-organized, the actual consistency and interactivity of the team remains stable. In fact, Dr. DiPaola was appointed as Director of CINJ following multiple appointments at CINJ including Co-Leader of the Prostate Program, Chief of Medical Oncology and Associate Director for Clinical Science. Dr. Edmund Lattime, a prior Associate Director, was appointed to the position of Deputy Director in 2008 by Dr. DiPaola. Dr. Joseph R. Bertino remains as Chief Scientific Officer. Dr. Michael Reiss continues as Associate Director for Translational Science and has appropriately assumed oversight of all basic science and translational shared resources. Dr. Eileen White, a Program Leader since 2004, was appointed Associate Director for Basic Science and, following a move of her laboratories to the main CINJ building in New Brunswick, increased basic science mentorship at CINJ. Dr. Joseph Aisner is Associate Director for Clinical Science as in the 2004 review, and Dr. Susan Goodin has been appointed Assistant Director for Clinical Science and Director ofthe Office of Human Research Services. Stability in administration also remains, as Ms. Linda Barker continues as Associate Director for Administration and Planning. As a new leader. Dr. Helmut Zarbl was appointed Associate Director for Public Health Science, overseeing CINJ's efforts in prevention, control, and population science. Salary support for these individuals is requested only for the effort attributable to research-related activities.

Public Health Relevance

The senior leadership supports the mission ofthe Cancer Institute of New Jersey (CINJ) as a National Cancer institute (NCI)-designated comprehensive cancer center to increase scientific depth and breadth in basic, clinical and public health sciences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA072720-17
Application #
8635979
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
17
Fiscal Year
2014
Total Cost
$1,383,785
Indirect Cost
$492,252
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08903
CeliĆ -Terrassa, Toni; Liu, Daniel D; Choudhury, Abrar et al. (2017) Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a-LCOR axis. Nat Cell Biol 19:711-723
Giovenco, Daniel P; Miller Lo, Erin J; Lewis, M Jane et al. (2017) ""They're Pretty Much Made for Blunts"": Product Features That Facilitate Marijuana Use Among Young Adult Cigarillo Users in the United States. Nicotine Tob Res 19:1359-1364
Delnevo, Cristine D; Giovenco, Daniel P; Miller Lo, Erin J (2017) Changes in the Mass-merchandise Cigar Market since the Tobacco Control Act. Tob Regul Sci 3:S8-S16
Chen, Jayson X; Liu, Anna; Lee, Mao-Jung et al. (2017) ?- and ?-tocopherols inhibit phIP/DSS-induced colon carcinogenesis by protection against early cellular and DNA damages. Mol Carcinog 56:172-183
Douam, Florian; Soto Albrecht, Yentli E; Hrebikova, Gabriela et al. (2017) Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo. MBio 8:
Delnevo, Cristine D; Hrywna, Mary; Giovenco, Daniel P et al. (2017) Close, but no cigar: certain cigars are pseudo-cigarettes designed to evade regulation. Tob Control 26:349-354
Sun, Yu; Sheshadri, Namratha; Zong, Wei-Xing (2017) SERPINB3 and B4: From biochemistry to biology. Semin Cell Dev Biol 62:170-177
Chesson, Charles B; Zloza, Andrew (2017) Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer. Nanomedicine (Lond) 12:2693-2706
Borrie, Melinda S; Campor, John S; Joshi, Hansa et al. (2017) Binding, sliding, and function of cohesin during transcriptional activation. Proc Natl Acad Sci U S A 114:E1062-E1071
Anantha, Rachel W; Simhadri, Srilatha; Foo, Tzeh Keong et al. (2017) Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. Elife 6:

Showing the most recent 10 out of 709 publications